Definium Therapeutics (DFTX) Net Income towards Common Stockholders Growth (1y) (2020 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -58.11% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -95.76% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 59.59% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -129.68% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -10.08% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1,228.66% |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | -154.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -154.05% |
| Dec 31, 2025 | -45.18% |
| Sep 30, 2025 | -205.14% |
| Jun 30, 2025 | -121.48% |
| Mar 31, 2025 | 44.22% |
| Dec 31, 2024 | -61.51% |
| Sep 30, 2024 | -9.26% |
| Jun 30, 2024 | 30.76% |
| Mar 31, 2024 | -177.86% |
| Dec 31, 2023 | -137.83% |
| Sep 30, 2023 | -22.39% |
| Jun 30, 2023 | -64.37% |
| Mar 31, 2023 | -5.80% |
| Dec 31, 2022 | 104.95% |
| Sep 30, 2022 | 4.13% |
| Jun 30, 2022 | 62.53% |
| Mar 31, 2022 | -24.65% |
| Dec 31, 2021 | 3,599.20% |
| Sep 30, 2021 | -98.22% |
| Jun 30, 2021 | -691.53% |
| Mar 31, 2021 | -111.08% |
| Dec 31, 2020 | 107.01% |